Featured Research

from universities, journals, and other organizations

Promising Approach In Prevention And Treatment Of Pancreatic Cancer

Date:
September 29, 2008
Source:
World Journal of Gastroenterology
Summary:
Pancreatic cancer is one of the most lethal human cancers and continues to be a major unsolved health problem. The overexpression of the epidermal growth factor receptor and its ligands correlates with rapidly progressive disease and resistance to chemotherapy.

Pancreatic cancer is one of the most lethal human cancers and continues to be a major unsolved health problem. The overexpression of the epidermal growth factor receptor and its ligands correlates with rapidly progressive disease and resistance to chemotherapy.

This study investigated the growth inhibitory effects of erlotinib in pancreatic cancer cells in vitro and in vivo.

Many gastrointestinal tumors, including pancreatic cancer, have been shown to overexpress the EGFR. The overexpression of EGFR correlates with rapidly progressive disease and poor prognosis. Targeting EGFR pathway as a potential therapeutic strategy for pancreatic cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial in pancreatic cancer revealed an improvement in survival with the addition of erlotinib. Treatment with anti-EGFR agents is used as a potential therapeutic strategy for pancreatic cancer, but the mechanisms are not yet precisely understood.

The research team from Department of Gastroenterology, Affiliated First People's Hospital, Shanghai Jiao Tong University, China studied the effects of erlotinib on six different pancreatic cancer cell lines. How erlotinib exhibits its antineoplastic activity in vivo needs to be further elucidated.

In this study authors revealed the efficacy of erlotinib, as a single agent, on pancreatic cancer cells growth in vitro, and in vivo study using a nude mice xenograft model and the mechanisms involved were also explored. Erlotinib repressed BxPC-3 cell growth in a dose-dependent manner, triggered G1 arrest and induced cell apoptosis,and suppressed capillary formation of endothelium in vitro.

In vivo, erlotinib treated mice demonstrated a reduced tumor volume and weight as compared with control. The relationship between EGFR and angiogenesis has also been investigated using tube formation assay in vitro and immunohistochemical analysis of tumor-associated blood vessels in vivo. These findings provide evidence for the inhibitive activity of erlotinib in pancreatic cancer cells. Inhibition of EGFR may be a promising adjuvant in chemotherapeutic strategy in the treatment of the dismal disease. The results also demonstrate that EGFR signaling pathway is an important target in pancreatic cancer.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lu et al. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World Journal of Gastroenterology, September 21, 2008; 14 (35): 5403 DOI: 10.3748/wjg.14.5403

Cite This Page:

World Journal of Gastroenterology. "Promising Approach In Prevention And Treatment Of Pancreatic Cancer." ScienceDaily. ScienceDaily, 29 September 2008. <www.sciencedaily.com/releases/2008/09/080925094715.htm>.
World Journal of Gastroenterology. (2008, September 29). Promising Approach In Prevention And Treatment Of Pancreatic Cancer. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2008/09/080925094715.htm
World Journal of Gastroenterology. "Promising Approach In Prevention And Treatment Of Pancreatic Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/09/080925094715.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins